Cargando…
Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma
PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with e...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446964/ https://www.ncbi.nlm.nih.gov/pubmed/23028479 http://dx.doi.org/10.1371/journal.pone.0043923 |
_version_ | 1782244050281168896 |
---|---|
author | Yamauchi, Mai Yamaguchi, Rui Nakata, Asuka Kohno, Takashi Nagasaki, Masao Shimamura, Teppei Imoto, Seiya Saito, Ayumu Ueno, Kazuko Hatanaka, Yousuke Yoshida, Ryo Higuchi, Tomoyuki Nomura, Masaharu Beer, David G. Yokota, Jun Miyano, Satoru Gotoh, Noriko |
author_facet | Yamauchi, Mai Yamaguchi, Rui Nakata, Asuka Kohno, Takashi Nagasaki, Masao Shimamura, Teppei Imoto, Seiya Saito, Ayumu Ueno, Kazuko Hatanaka, Yousuke Yoshida, Ryo Higuchi, Tomoyuki Nomura, Masaharu Beer, David G. Yokota, Jun Miyano, Satoru Gotoh, Noriko |
author_sort | Yamauchi, Mai |
collection | PubMed |
description | PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with epidermal growth factor (EGF) in the presence or absence of a clinically used EGF receptor tyrosine kinase (RTK)-specific inhibitor, gefitinib. The data were subjected to a mathematical simulation using the State Space Model (SSM). “Gefitinib-sensitive” genes, the expressional dynamics of which were altered by addition of gefitinib, were identified. A risk scoring model was constructed to classify high- or low-risk patients based on expression signatures of 139 gefitinib-sensitive genes in lung cancer using a training data set of 253 lung adenocarcinomas of North American cohort. The predictive ability of the risk scoring model was examined in independent cohorts of surgical specimens of lung cancer. RESULTS: The risk scoring model enabled the identification of high-risk stage IA and IB cases in another North American cohort for overall survival (OS) with a hazard ratio (HR) of 7.16 (P = 0.029) and 3.26 (P = 0.0072), respectively. It also enabled the identification of high-risk stage I cases without bronchioalveolar carcinoma (BAC) histology in a Japanese cohort for OS and recurrence-free survival (RFS) with HRs of 8.79 (P = 0.001) and 3.72 (P = 0.0049), respectively. CONCLUSION: The set of 139 gefitinib-sensitive genes includes many genes known to be involved in biological aspects of cancer phenotypes, but not known to be involved in EGF signaling. The present result strongly re-emphasizes that EGF signaling status in cancer cells underlies an aggressive phenotype of cancer cells, which is useful for the selection of early-stage lung adenocarcinoma patients with a poor prognosis. TRIAL REGISTRATION: The Gene Expression Omnibus (GEO) GSE31210 |
format | Online Article Text |
id | pubmed-3446964 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-34469642012-10-01 Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma Yamauchi, Mai Yamaguchi, Rui Nakata, Asuka Kohno, Takashi Nagasaki, Masao Shimamura, Teppei Imoto, Seiya Saito, Ayumu Ueno, Kazuko Hatanaka, Yousuke Yoshida, Ryo Higuchi, Tomoyuki Nomura, Masaharu Beer, David G. Yokota, Jun Miyano, Satoru Gotoh, Noriko PLoS One Research Article PURPOSE: To identify stage I lung adenocarcinoma patients with a poor prognosis who will benefit from adjuvant therapy. PATIENTS AND METHODS: Whole gene expression profiles were obtained at 19 time points over a 48-hour time course from human primary lung epithelial cells that were stimulated with epidermal growth factor (EGF) in the presence or absence of a clinically used EGF receptor tyrosine kinase (RTK)-specific inhibitor, gefitinib. The data were subjected to a mathematical simulation using the State Space Model (SSM). “Gefitinib-sensitive” genes, the expressional dynamics of which were altered by addition of gefitinib, were identified. A risk scoring model was constructed to classify high- or low-risk patients based on expression signatures of 139 gefitinib-sensitive genes in lung cancer using a training data set of 253 lung adenocarcinomas of North American cohort. The predictive ability of the risk scoring model was examined in independent cohorts of surgical specimens of lung cancer. RESULTS: The risk scoring model enabled the identification of high-risk stage IA and IB cases in another North American cohort for overall survival (OS) with a hazard ratio (HR) of 7.16 (P = 0.029) and 3.26 (P = 0.0072), respectively. It also enabled the identification of high-risk stage I cases without bronchioalveolar carcinoma (BAC) histology in a Japanese cohort for OS and recurrence-free survival (RFS) with HRs of 8.79 (P = 0.001) and 3.72 (P = 0.0049), respectively. CONCLUSION: The set of 139 gefitinib-sensitive genes includes many genes known to be involved in biological aspects of cancer phenotypes, but not known to be involved in EGF signaling. The present result strongly re-emphasizes that EGF signaling status in cancer cells underlies an aggressive phenotype of cancer cells, which is useful for the selection of early-stage lung adenocarcinoma patients with a poor prognosis. TRIAL REGISTRATION: The Gene Expression Omnibus (GEO) GSE31210 Public Library of Science 2012-09-19 /pmc/articles/PMC3446964/ /pubmed/23028479 http://dx.doi.org/10.1371/journal.pone.0043923 Text en © 2012 Yamauchi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Yamauchi, Mai Yamaguchi, Rui Nakata, Asuka Kohno, Takashi Nagasaki, Masao Shimamura, Teppei Imoto, Seiya Saito, Ayumu Ueno, Kazuko Hatanaka, Yousuke Yoshida, Ryo Higuchi, Tomoyuki Nomura, Masaharu Beer, David G. Yokota, Jun Miyano, Satoru Gotoh, Noriko Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title | Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title_full | Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title_fullStr | Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title_full_unstemmed | Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title_short | Epidermal Growth Factor Receptor Tyrosine Kinase Defines Critical Prognostic Genes of Stage I Lung Adenocarcinoma |
title_sort | epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage i lung adenocarcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446964/ https://www.ncbi.nlm.nih.gov/pubmed/23028479 http://dx.doi.org/10.1371/journal.pone.0043923 |
work_keys_str_mv | AT yamauchimai epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT yamaguchirui epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT nakataasuka epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT kohnotakashi epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT nagasakimasao epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT shimamurateppei epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT imotoseiya epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT saitoayumu epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT uenokazuko epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT hatanakayousuke epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT yoshidaryo epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT higuchitomoyuki epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT nomuramasaharu epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT beerdavidg epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT yokotajun epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT miyanosatoru epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma AT gotohnoriko epidermalgrowthfactorreceptortyrosinekinasedefinescriticalprognosticgenesofstageilungadenocarcinoma |